Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%
GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern -22% 14%
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif -44% demonstrated58%
HC-nCoV (Shanghai), 2020
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive 0%
Libster, 2020
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%
7 studies excluded by filtering options (5 RCT / 2 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).